Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Study Phase: Phase 2
Recruitment Status: Recruiting
Start Date: May 07, 2021
End Date: October 01, 2023
Inclusion Criteria:
- Willing to participate in the study and provide written informed consent.
- Male and female adults aged > 18 years.
- Must have NASH and fibrosis on a liver biopsy sample
- If a historical liver biopsy is used for Screening, obtained within 6 months prior to Screening;
- Subjects may have a diagnosis of T2DM
Exclusion Criteria:
- History or presence of liver disease (other than NAFLD or NASH)
- History or presence of cirrhosis and/or history or presence of hepatic decompensation
-
Conditions:
- Fatty Liver
- Non-alcoholic Fatty Liver Disease
- Fibrosis